RPPH1 and syringocystadenoma papilliferum: Additionally, RPPH1 (95% CI = 0.147–0.963) and PCT (95% CI = 1.040–6.238) were identified as prognostic factors of SCAP patients with the hazard ratio of 0.377 and 2.547, respectively (Fig. 3B).